Led by Sofinnova Partners and Earlybird Venture Capital, Haya Therapeutics’ Series A funding round also involved a syndicate of investors, including Eli Lilly and Company. The investment will be used to advance the clinical development of its lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. .

由索菲诺瓦合作伙伴和早期鸟类风险投资公司领投，Haya Therapeutics的A轮融资还涉及一个投资者财团，包括礼来公司。这笔投资将用于推进其主要的长链非编码RNA（lncRNA）靶向候选药物HTX-001在心力衰竭中的临床开发，并继续扩展其RNA引导的调控基因组管道开发引擎。

HAYA Therapeutics

海雅治疗学公司

is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprietary platform maps and decodes the biology of the regulatory genome, also referred to as the “.

是一家生物技术公司，率先开发精确的RNA引导的调控基因组靶向治疗药物，这些药物可以重新编程导致疾病的细胞状态，用于治疗罕见病、常见病、慢性病和与年龄相关的疾病。HAYA专有平台的核心是绘制和解码调控基因组的生物学，也被称为“。

genome’s dark matter” or “Dark Genome

基因组的暗物质“或”暗基因组

”

“

, which constitutes 98% of the human genome. While the regulatory genome does not code for proteins, it is now recognized as the master control layer of gene expression and cell identity.

，这部分占据了人类基因组的98%。虽然调控基因组不编码蛋白质，但它现在被认为是基因表达和细胞身份的主控层。

HAYA has developed the most comprehensive atlas of the regulatory genome by combining integrated multimodal functional genomics with a stack of proprietary computational and machine learning methodologies, enabling the precise identification and modulation of pathogenic cell states across diverse diseases.

HAYA通过将综合多模态功能基因组学与一系列专有的计算和机器学习方法相结合，开发了最全面的调控基因组图谱，能够精准识别和调节跨多种疾病的致病细胞状态。

HAYA’s regulatory genome platform enables the development of RNA-guided therapeutics with unprecedented precision, speed and scalability. This next-generation approach is designed to go beyond symptom management and directly reprogram the cellular drivers of disease..

HAYA的监管基因组平台能够以前所未有的精确度、速度和可扩展性开发RNA引导的治疗药物。这种下一代方法旨在超越症状管理，直接重新编程疾病的细胞驱动因素。

The $65 million from its Series A funding will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. The round was led by

HAYA公司在A轮融资中获得的6500万美元将加速其主要候选药物HTX-001（靶向长链非编码RNA（lncRNA））在心力衰竭领域的临床开发，并继续扩展其RNA引导的调控基因组管道开发引擎。本轮融资由

Sofinnova Partners

索菲诺瓦合伙人

and

和

Earlybird Venture Capital

早期风险投资

, with participation from

，参与方包括

Eli Lilly and Company (Lilly)

礼来公司 (Lilly)

,

，

ATHOS

阿多斯

,

，

+ND Capital

+ND资本

,

，

Alexandria Venture Investments

亚历山大风险投资

and

和

LifeLink Ventures

生命链接风险投资公司

, with additional support from existing investors

，现有投资者额外支持

Apollo Health Ventures

阿波罗健康风险投资公司

,

，

Longview Ventures

长景创投

(an affiliate of Broadview Ventures),

（Broadview Ventures的附属机构），

4see ventures

4see风险投资

,

，

BERNINA Bioinvest

伯尼纳生物投资

and

和

Schroders Capital

施罗德资本

.

。

“This is a defining moment for HAYA as we are advancing our lead program into the clinic. This funding validates our organization, pioneering approach and vision for improving the way chronic and complex diseases are treated by creating a new generation of therapies that reprogram disease-driving cell states into healthy ones,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics.

“这是HAYA的一个决定性时刻，因为我们正在将我们的主导项目推进到临床阶段。这笔资金肯定了我们的组织、开创性的方法以及通过创造新一代疗法来改善慢性病和复杂疾病治疗方式的愿景，这些疗法可以将致病细胞状态重新编程为健康状态，”HAYA Therapeutics的联合创始人兼首席执行官Samir Ounzain博士表示。

“We’re excited that Sofinnova Partners, Earlybird and our syndicate of investors share our vision for the potentially industry changing nature of our platform as we move beyond traditional approaches by leveraging novel therapeutic targets emerging from the regulatory genome.”.

“我们感到兴奋的是，Sofinnova Partners、Earlybird 以及我们的投资者财团认同我们对平台可能带来行业变革的愿景，因为我们通过利用来自调控基因组的新型治疗靶点，超越了传统方法。”

The company will use the funds to initiate clinical trials for HTX-001, HAYA’s first-in-class lncRNA-targeting therapy for heart failure, initially focused on non-obstructive hypertrophic cardiomyopathy (nHCM). In parallel, the company will strengthen its platform capabilities and expand its pipeline of disease-modifying therapies across multiple therapeutic areas—including pulmonary fibrosis, obesity and age-related common and chronic diseases..

公司将利用这笔资金为 HTX-001 启动临床试验，HTX-001 是 HAYA 首个针对心力衰竭的一流 lncRNA 靶向疗法，最初专注于非梗阻性肥厚型心肌病 (nHCM)。同时，公司还将加强其平台能力，并扩大其在多个治疗领域内的疾病修饰疗法管线，包括肺纤维化、肥胖症以及与年龄相关的常见和慢性疾病。

“HAYA’s platform unlocks the dark genome’s therapeutic potential by targeting disease-driving cell states via long non-coding RNAs. This novel approach opens a new frontier in precision medicine, moving beyond traditional target classes to address disease at its epigenetic and cellular roots. Leading this round alongside Earlybird reflects our deep conviction in the HAYA team and their mission to develop safer, more effective therapies across a broad range of indications, including their lead program in nHCM, as they advance it toward the clinic to address a major unmet need,” noted Henrijette Richter, Managing Partner at Sofinnova Partners..

“HAYA的平台通过长链非编码RNA靶向疾病驱动的细胞状态，释放了暗基因组的治疗潜力。这一新颖的方法开启了精准医学的新前沿，超越了传统的靶点类别，从表观遗传和细胞根源上解决疾病问题。Earlybird与我们共同领投此轮，体现了我们对HAYA团队及其使命的深切信任，他们致力于开发更安全、更有效的疗法，涵盖广泛的适应症，包括他们在nHCM领域的主导项目，随着其向临床推进，将满足一项重大的未满足需求，”Sofinnova Partners的管理合伙人Henrijette Richter指出。

(Press release/RAN)

（新闻稿/拉美通讯社）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送